We are pleased to share that earlier this December, ERDERA opened its 2026 Joint Transnational Call on “Resolving unsolved cases in rare genetic and non genetic diseases”. Interested multinational research teams can now access the call documents, set up a consortium and prepare their pre-proposal in the electronic submission system. Key dates:– Pre-proposal deadline: 12 February […]
Read More
IRDiRC’s Patient Advocacy Constituent Committee member, EURORDIS-Rare Diseases Europe is organizing a new edition of the European Conference on Rare Diseases & Orphan Products (ECRD), the largest patient-led policy-shaping event on rare diseases in Europe. Taking place five years after Rare2030 and midway to the 2028 World Health Organization Global Plan target, ECRD 2026 will bring Europe’s […]
Read More
A new IRDiRC feature article published in Drug Discovery Today provides a comprehensive assessment of non-oncology orphan drug development, focusing on productivity and the probability of success for therapies targeting rare diseases outside of cancer. The article, titled “Non-oncology orphan drug development: Productivity and probability of success, highlights several important trends: While rare diseases collectively affect hundreds of millions of […]
Read More
A global community of clinicians, patient leaders, regulators and researchers met in Heidelberg (Germany) and online for the second International Conference on Clinical Research Networks (CRNs), organised by the European Rare Diseases Research Alliance (ERDERA), Rare Diseases International (RDI) and the International Rare Diseases Research Consortium (IRDiRC). CRNs are structured collaborations of expert sites, laboratories, […]
Read MoreIRDiRC is pleased to announce that COMBINEDBrain, represented by Terry Jo Bichell (CEO), has joined the IRDiRC Patient Advocacy Constituent Committee (PACC). The Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders is a non-profit organization devoted to speeding the path to clinical treatments for people with rare genetic neurodevelopmental disorders by pooling efforts, studies, and data. […]
Read MoreThe International Rare Diseases Research Consortium Diagnostics Scientific Committee (DSC) has created a Survey on Regulation, Accreditation, and Quality Assessment of Genetic Laboratories. This survey has been developed to map the global regulatory and quality landscape for genetic testing laboratories. The results will help identify best practices, gaps, and opportunities to harmonize standards for diagnostic laboratories worldwide. The survey is available at the following link: Survey […]
Read MoreWe are pleased to announce that Stefano Benvenuti, Head of Public Affairs at Fondazione Telethon (Italy), and Naveed Aziz, Vice President of Research and Innovation at Genome Canada (Canada), have been elected as the Chair and Vice Chair, respectively, of the Funders Constituent Committee (FCC). About the FCC The IRDiRC Funders Constituent Committee’s principal mission is to ensure high-level coordination […]
Read More
Want to stay informed about the latest breakthroughs, global initiatives, and collaborative efforts shaping the future of rare disease research? Join the International Rare Diseases Research Consortium (IRDiRC) community by subscribing to our newsletter. Why Subscribe? By signing up, you’ll receive: Who Is It For? Researchers, clinicians, industry partners, patient advocates, regulators, policymakers, and anyone committed to […]
Read More
A new analysis of orphan drug approvals across six global regulatory regions highlights significant delays in access to innovative therapies for people living with rare diseases. The study, conducted by the International Rare Diseases Research Consortium (IRDiRC) Regulatory Science Committee (RSC), examined all new non-oncology orphan medicines approved between 2021 and 2022 and found substantial […]
Read MoreThe International Rare Diseases Research Consortium (IRDiRC) is pleased to announce the appointment of Shekhar Natarajan (Vice President, Head of EU and International Regulatory Affairs at Dyne Therapeutics, USA), as Chair, and Diana Kwast-Hoekstra (Executive Director at (Un)limited Forward!, Netherlands), as Vice Chair of the Therapies Scientific Committee (TSC). The TSC unites a diverse group of stakeholders from across the global […]
Read More